Golcadomide ± Rituximab in Relapsed/Refractory Large B-cell Lymphoma | Julio Chavez, MD, MS | #ASH24

Golcadomide ± Rituximab in Relapsed/Refractory Large B-cell Lymphoma | Julio Chavez, MD, MS | #ASH24
Mosunetuzumab + Polatuzumab Shows Promising Outcomes in LBCL | Julio Chavez, MD, MS | #ASH24
Mosunetuzumab + Polatuzumab Shows Promising Outcomes in LBCL | Julio Chavez, MD, MS | #ASH24
Mosunetuzumab + Polatuzumab Shows Promising Outcomes in LBCL
Myeloma 11 Trial: Carfilzomib Quadruplet Enhances Overall Survival | Charlotte Pawlyn, MD | #ASH24
Factors Influencing Enrollment in Hematologic Cancer Trials (2008-2023) | Rupayan Kundu, MD | #ASH24
Barriers to Stem Cell Transplant in #AML: NC Cohort Insights | Michele Sainvil, MD | #ASH24
Barriers to Stem Cell Transplant in #AML: NC Cohort Insights | Michele Sainvil, MD | #ASH24
ASH 2024 Wrap-Up: What's next in #Myeloma Treatment | Claudio Cerchione, MD | #ASH24
ASH 2024 Wrap-Up: What's next in #Myeloma Treatment | Claudio Cerchione, MD | #ASH24
ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach, MD, Cyril Konto, MD | #ASH24
ISB 2001 in Relapsed/Refractory #Myeloma: Phase 1 Results | Hang Quach, MD, Cyril Konto, MD | #ASH24